Atsena Therapeutics closes $150 million Series C financing

North Carolina, USA-based clinical-stage gene therapy company Atsena Therapeutics has announced the successful closing of an oversubscribed $150 million Series C financing.

The financing was led by Bain Capital’s Life Sciences team, with participation from an additional new investor, Wellington Management. All the company’s existing investors also participated in the round, including Lightstone Ventures, Sofinnova Investments, Abingworth, Foundation Fighting Blindness, Hatteras Venture Partners, Osage University Partners, and the Manning Family Foundation.

Atsena said that proceeds from the financing will be used to advance its lead program, ATSN-201, for the treatment of X-linked retinoschisis (XLRS), a genetic condition that is typically diagnosed in childhood and leads to blindness later in life. The proceeds will also support Atsena’s pre-clinical pipeline of first-in-class therapies and expand the use of Atsena’s novel spreading AAV.SPR capsid. Currently, no approved treatments for XLRS exist.